2018 American Transplant Congress » Poster Session A: Kidney Immunosuppression: Desensitization

5:30pm-7:30pm

Anti-IdeS Antibodies in IVIg and Its Effect on IdeS Activity

A. Runström,¹ S. Järnum,¹ S. Jordan,² L. Winstedt,¹ C. Kjellman.¹

5:30pm-7:30pm

B-Cell Depletion with Rituximab Exacerbates Anti-Donor CD4⁺ T-Cell Responses in Patients with Donor-Specific Anti-Human Leukocyte Antigen Antibodies

A. Tanaka, K. Ide, Y. Tanaka, M. Ohira, H. Tahara, S. Shimizu, H. Ohdan.

5:30pm-7:30pm

Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute

H. Harada, Y. Wada, A. Mitsuke, T. Hirose, N. Fukuzawa, T. Seki.

5:30pm-7:30pm

Decreased Clinical Significance of Isoagglutinin Titer with the Current Desensitization Protocol in ABO-Incompatible Kidney Transplantation

C. Baek, H. Kim, W. Yang, D. Han, S-.K. Park.

5:30pm-7:30pm

Delayed Graft Function in Live Donor HLA-Incompatible Kidney Transplant Recipients: A Multicenter Study

J. Motter,¹ A. Massie,¹ J. Garonzik Wang,¹ K. Jackson,¹ X. Luo,¹ A. Muzaale,¹ B. Orandi,² D. Segev.¹

5:30pm-7:30pm

Efficacy of IVIG + Rituximab Desensitization Therapy on HLA Antibodies is Independent of HLA Loci

X. Zhang,¹ S. Jordan.²

5:30pm-7:30pm

Elevated Levels of CD19⁺ B Cells before or after Rituximab Administration is a Risk Factor for the Early Rejection of a Living Kidney Transplant

M. Kono,¹ H. Shirakawa,² S. Wakai.¹

5:30pm-7:30pm

HLA Desensitization Using Rituximab/ Immunoadsorption before Kidney Transplantation

P. Malvezzi, T. Jouve, D. Masson, J. Maurizi, B. Bardy, P-.L. Carron, B. Janbon, N. Terrier, L. Rostaing.

5:30pm-7:30pm

Immuoadsorption-Based Desensitization in Highly Sensitized Patients Awaiting Deceased Donor Kidney Transplantation.

C. Bureau, P. Galichon, Y. Luque, N. Ouali, E. Rondeau, C. Rafat.

5:30pm-7:30pm

Mid-Term Outcome of Donor Specific Antibody Positive Deceased Donor Kidney Transplantation with Peri-Transplant Desensitization

K. Osickova,¹ P. Hruba,² J. Slatinska,¹ A. Slavcev,² J. Fronek,² E. Honsova,² O. Viklicky.¹

5:30pm-7:30pm

Non Active Desensitization Protocol: Improving Access to Kidney Transplant for Hyperimmunized Patients

S. Le Bot,¹ F. Delbos,² C. Garandeau,¹ S. Malard Castagnet,² A. Cesbron,² M. Hourmant.¹

5:30pm-7:30pm

Pre-Emptive Rituximab and Intravenous Immunoglobulin (IVIg) Fail to Prevent Rejection in Kidney Transplant Recipients (KTx) with Donor Specific Antibodies (DSA)

J. Crew, R. Vasilescu, E. Campenot, S. Mohan, S. Patel.

5:30pm-7:30pm

The Clinical Significance of Pretransplant C1q Assay Status in Positive Crossmatch Kidney Transplantation

J. Lee,¹ D. Kim,¹ B. Park,² S. Song,³ J. Lee,⁴ Y. Jung,¹ J. Lee,¹ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹

5:30pm-7:30pm

The Results of Plasmapheresis and Anti-CD20 Based Desensitization without Intravenous Immunoglobulin in Positive Crossmatch Kidney Transplants

H. Kwon, Y. KIm, J. Choi, S. Shin, J. Jung, M. Cho, J. Kim, D. Han.